Indian Immunologicals Ltd. to invest Rs700 crore in Hyderabad to build a new facility

11 Oct 2022 , 08:31 AM

National Dairy Development Board (NDDB)-owned Indian Immunologicals Limited (IIL), a public sector vaccine manufacturer, announced on Monday that it will invest Rs700 crore to build a brand-new animal vaccine manufacturing plant in Genome Valley, Hyderabad.

The proposed facility will produce vaccines for developing diseases like Foot and Mouth disease (FMD). Approximately 750 people will be employed overall as a result of the project.

The facility is designed to be a cutting-edge, fully integrated biosafety level 3 (BSL-3) facility for the manufacturing of drug substances (DS) and their corresponding fill-finish.

The proposed plant will increase the capacity of the FMD vaccination by 300 million doses annually. The current Gachibowli, Hyderabad, facility has a 300 million dosage capacity. It is anticipated that production would start in the third year.

IIL is a leading supplier of FMD vaccine to the Government of India’s National Animal Disease Control Program and currently produces over 150 products. It is also one of the largest makers of FMD vaccine in the world (NADCP).

For feedback and suggestions, write to us at [e-mail]